SLC5A2 and chronic kidney disease: Secondary analyses of DAPA-CKD and EMPA-KIDNEY consistently showed the efficacy of SGLT2 inhibitors in patients with glomerulonephritis, with both studies confirming the efficacy of SGLT2 inhibitors in this patient population.